CEACAM1-induced drugs enhance chemosensitivity of Hepatoblastoma
| Project/Area Number |
26861486
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Pediatric surgery
|
|---|
| Research Institution | Wakayama Medical University |
|---|
Principal Investigator |
Mitani Yasuyuki 和歌山県立医科大学, 医学部, 学内助教 (40612106)
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
Fiscal Year 2016: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2015: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Keywords | 肝芽腫 / CEACAM1 / CDDP |
|---|
| Outline of Final Research Achievements |
In a clinical study, CEACAM1 expression suggest the benign prognostic factor in hepatoblastoma. Suppression of CEACAM1 expression in hepatblastoma cell lines reduces the effect of cancer drugs (CDDP). All-trans retinoic acid (ATRA) induces the CEACAM1 expression in hepatblastomat cell lines, and combination with ATRA and CDDP enhance the effect of CDDP. CEACAM1 short isoform expression in hepatblastoma cell lines is associated with chemosensitivity.
|
Report
(4 results)
Research Products
(1 results)
